Please assess the completion status of the following clinical trial:

Trial Title: Effect of Denosumab in Erosion Healing in RA

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* ≥18 years old~* DAS28 ≤5.1~* without severe deformity in MCP joints which would influence the longitudinal assessment of HR-pQCT~Exclusion Criteria:~* RA functional status class IV (limited in ability to perform usual self-care, vocational, and avocational activities)~* treatment with any biologic DMARDs for RA treatment within 8 weeks before randomisation~* pregnancy or premenopausal women planning pregnancy~* previous use of denosumab, zoledronic acid or teriparatide~* Hyperparathyroidism~* contraindications to denosumab~* Bisphosphonate, biologic DMARDs and the use of oral glucocorticoid \>10 mg/day (prednisolone equivalent)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Denosumab (Type: ACTIVE_COMPARATOR): Subcutaneous injections of denosumab 60mg will be given in 4 doses at each visit (at baseline, 6, 12 and 18 months).
- Placebo (Type: PLACEBO_COMPARATOR): Subcutaneous injections of placebo (0.9% Sodium Chloride solution) will be given in 4 doses at each visit (at baseline, 6, 12 and 18 months).

Based on this trial design, predict the completion outcome and termination type (if applicable).